A 62-year-old woman from Mumbai with a 3-year history of chronic lymphocytic leukemia (CLL) presents with progressive lymphadenopathy and splenomegaly. Recent CBC shows lymphocyte count 45,000/µL. Flow cytometry confirms CD5+, CD19+, CD23+ B-cell phenotype. She is asymptomatic with Rai stage II disease and normal renal and hepatic function. Genetic testing shows deletion 13q as the sole abnormality. What is the most appropriate next step in management?

Explanation

## Watch-and-Wait Strategy in Early-Stage CLL **Key Point:** Asymptomatic early-stage CLL (Rai stage I–II) with favorable genetics (del 13q) does not require immediate treatment. The "watch-and-wait" approach delays chemotherapy until symptomatic progression or high-risk features emerge, improving quality of life without compromising survival. ## CLL Risk Stratification and Treatment Timing ```mermaid flowchart TD A[CLL Diagnosed]:::outcome --> B{Symptoms or Rai ≥ II with adverse features?}:::decision B -->|Yes| C[Initiate Treatment]:::action B -->|No| D[Assess Genetics]:::decision D -->|del 13q only| E[Watch and Wait]:::action D -->|del 11q or TP53 mut| F[Consider Early Treatment]:::action D -->|Trisomy 12| G[Intermediate: Individualize]:::decision E --> H[Monitor CBC, LDH, β2-microglobulin q3-6mo]:::action H --> I{Progressive disease?}:::decision I -->|Yes| J[Start TKI or Chemoimmunotherapy]:::action I -->|No| K[Continue observation]:::action ``` ## Prognostic Markers in CLL | Marker | Prognosis | Median OS | |--------|-----------|----------| | **del 13q (sole)** | Favorable | >10 years | | **Normal karyotype** | Intermediate | 5–8 years | | **Trisomy 12** | Intermediate | 5–8 years | | **del 11q** | Adverse | 5–8 years | | **del 17p / TP53 mut** | Very adverse | <2 years | **High-Yield:** Rai stage II with del 13q as the sole abnormality is a favorable-risk CLL. Asymptomatic patients do not benefit from early treatment and should be observed. **Clinical Pearl:** The "watch-and-wait" approach has been validated in multiple randomized trials (e.g., CLL5 trial) showing no survival disadvantage compared to immediate treatment, while reducing cumulative toxicity. ## Indications to Initiate Treatment in CLL 1. **Symptomatic disease:** B symptoms (fever, night sweats, weight loss ≥10% in 6 months) 2. **Progressive marrow failure:** Hemoglobin <11 g/dL or platelets <100,000/µL due to CLL 3. **Massive/progressive lymphadenopathy or organomegaly** causing symptoms 4. **Lymphocyte doubling time <6 months** (indicates aggressive biology) 5. **Adverse genetics** (del 17p, TP53 mutation, del 11q) even if asymptomatic **Mnemonic:** **WATCH** = **W**ait for symptoms, **A**void early chemo, **T**rack with labs, **C**onsider genetics, **H**old unless high-risk ## Why Other Options Are Incorrect - **Fludarabine + cyclophosphamide:** Chemotherapy is toxic and should not be given to asymptomatic patients with favorable genetics. Reserved for symptomatic or high-risk disease. - **Venetoclax monotherapy:** BCL2 inhibitor is effective but should not be started without indication; reserved for relapsed/refractory CLL or high-risk disease. - **TP53 testing without clinical indication:** TP53 mutation testing is not routine in favorable-risk del 13q disease. It is indicated in del 17p, del 11q, or if considering early treatment. [cite:Harrison 21e Ch 105; Robbins 10e Ch 13]